4D Path, a company personalizing cancer care through a physics-informed approach to predict tumor response to therapy, has announced the first close of a strategic financing round alongside the appointment of two seasoned healthcare executives to its board of directors. Katherine Vega Stultz will serve as Board Chair, and Robert J. Hombach joins as a director.
4D Path’s platform, the patented Q-Plasia OncoReader, is designed to measure and quantify cell cycle deregulation and tumor immune microenvironment dynamics to predict patient response to therapy. The company has delivered clinically relevant results across breast, ovarian, colorectal and skin cancers and across multiple treatment modalities.
Stultz brings decades of leadership in strategy, clinical development and commercialization, including directing the clinical project organization at Celgene across more than 30 mid and late-stage programs in hematology and oncology. She is currently CEO and President of BrainXell Therapeutics Global Inc. Hombach previously served as EVP, CFO and COO of Baxalta, a $6 billion global biopharmaceutical company acquired by Shire in 2016, and as CFO of Baxter.
The financing will accelerate the development of treatment predictive biomarkers for 4D Path-sponsored clinical use and partnerships with biopharma companies. The Newton, Massachusetts-based company has demonstrated pan-cancer potential across early-stage and metastatic cases.
KEY QUOTES:
“Their addition coupled with our strategic financing will serve as a catalyst to bring this promising treatment predictive technology one step closer to helping patients around the world beat cancer.”
Jacopo Leonardi, CEO, 4D Path
“I am thrilled to be a part of the 4D Path growth story as the company embarks on further generating clinical evidence and advancing partnerships to better identify the most appropriate treatment approach for an individual patient.”
Katherine Vega Stultz, Board Chair, 4D Path
